PYXS (Pyxis Oncology) Stock Based Compensation: $9.38 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PYXS Pyxis Oncology Inc PYXS
26 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Pyxis Oncology Stock Based Compensation?

Pyxis Oncology PYXS +13.17% 26 Stock Based Compensation is $9.38 Mil as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Pyxis Oncology's Stock Based Compensation for the three months ended in Mar. 2026 was $1.21 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $9.38 Mil.

Pyxis Oncology Stock Based Compensation Related Terms

Pyxis Oncology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pyxis Oncology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pyxis Oncology Stock Based Compensation Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 6.44 15.76 16.95 12.95 11.80

Pyxis Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.02 3.07 2.08 1.21
PYXS
26GF Score
Pyxis Oncology Inc PYXS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pyxis Oncology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.38 Mil.

What does a Stock Based Compensation of $9.38 Mil mean?
Pyxis Oncology (PYXS) has a Stock Based Compensation of $9.38 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pyxis Oncology and its competitors.
Is Pyxis Oncology's Stock Based Compensation too high?
Pyxis Oncology's current Stock Based Compensation is $9.38 Mil. Overall, Pyxis Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Stock Based Compensation compare to ORMP and CAMP?
Pyxis Oncology's Stock Based Compensation of $9.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pyxis Oncology and its competitors. Pyxis Oncology's current Stock Based Compensation is $9.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Stock Based Compensation of $9.38 Mil. The current Stock Based Compensation is $9.38 Mil. Pyxis Oncology's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Stock Based Compensation is $9.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pyxis Oncology Business Description

Address 321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
26GF Score

Get the complete analysis for PYXS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price